Boston Scientific Corporation vs Roundhill NVDA WeeklyPay ETF — how do they compare? Boston Scientific Corporation trades at $42.86 (market cap $66.37B), while Roundhill NVDA WeeklyPay ETF trades at $37.48. The key difference: Roundhill NVDA WeeklyPay ETF is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | NVDW | |
|---|---|---|
Market Cap | $66.37B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $108.14 | $53.42 |
52-Week Low | $42.63 | $31.88 |
Enterprise Value | $75.94B | — |
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
NVDW trades at $35.81, down 4.66% over the past day, with technical indicators showing mixed signals—bullish oscillators but bearish moving averages. The stock has a history of frequent dividend payments, with recent payouts ranging from $0.21 to $0.48 per share. Key support is near $35, while resistance levels start at $38.
The outlook hinges on NVDW's ability to maintain its dividend stream amid market volatility. Risks include dependency on underlying asset performance and payout fluctuations. Upside potential exists if technical resistance is broken, but investors should monitor earnings stability and broader market trends.
Trailing returns across standard periods
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →NVDW is an actively managed ETF that seeks to provide weekly distributions and returns equal to 1.2 times (120%) the calendar week performance of Nvidia (NVDA) common shares. It combines modest leverage with a high-frequency payout schedule, designed for investors who want amplified exposure to Nvidia alongside a consistent weekly income stream.
Read more on NVDW →